Band 7+: The chart below shows how much money five big pharmaceutical companies spent on research in 2012 and 2018 and gives an estimate of the amounts spent in 2022. Describe the data providing an overview of the general trends, reporting the main features, and making comparisons.

The bar chart shows the amount of investments into pharmaceutical research done by five leading companies from 2012 to 2018 and predictions for 2022.

All companies show an upward trend in investments, with the most amount of money spent by Novas in 2018. Moreover, it has been estimated that this company will continue to be the leading investor in 2022.

In 2012, Pharm spent a bit under 10 billion on research. However, it has increased its investments only to around 12-13 billion in 2018. Meanwhile, Novas has quadrupled monetary support during those years, going from around 4 billion to nearly 20. Despite being nearly absent from research support in 2012, Biopharm has raised its spending for research to just over 5 billion.

In the year 2022, it is estimated that Novas would triple its investments, bringing them to nearly 60 billion. Moreover, Biopharm is also predicted to have a sharp increase to around 25 billion. Furthermore, other companies’ investments are likely to double.